SRPT - Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy | Benzinga
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consensus of $939.14 million.
Overall, organic net revenue decreased by 8% over the same period.
Q1 24 net loss of $(715) million includes non-cash goodwill impairment charges of $700 million.
Adjusted net loss was $(19) million, or $(0.10) per diluted share, compared to adjusted net income of $61 million, or $0.34 per diluted share, a year ago, beating the consensus of $(0.14).
Guidance: Catalent reaffirms FY24 sales guidance of $4.3 billion-$4.5 billion versus the